Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
GLICLAZIDE SANDOZ MR (Sandoz Pty Ltd)
Product name
GLICLAZIDE SANDOZ MR
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
146 (255 working days)
Active ingredients
Gliclazide
Registration type
New generic medicine
Indication
GLICLAZIDE SANDOZ MR (modified release tablet) is indicated for Type II diabetes in association with dietary measures when dietary measures alone are inadequate to control blood glucose.
During controlled clinical trials in patients with type II diabetes, a modified release formulation of gliclazide (30 mg - 120 mg), taken as a single daily dose, was shown to be effective long term in controlling blood glucose levels, based on monitoring of HbA1c.